Clinical Commander

Back to dossier
msk.gout-chronic.core.v1PRODUCTION
msk.gout-chronic.core.v1

Chronic gout — urate-lowering therapy (treat-to-target)

rheumatologychronicadultgeriatric
Hard-required inputs
0 / 9
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Adult/geriatric established or recurrent gout — the longitudinal urate-lowering arc to treat-to-target and dissolve crystal burden. Acute-flare abortive therapy is NOT in scope (route to msk.gout-acute.core.v1). Disease is curable below the MSU saturation point ~6.8 mg/dL (ACR 2020 FitzGerald PMID 32391934; EULAR 2016 Richette PMID 27457514)

Inputs
2
Actions
0
Advance rule
Set
Advance when

Chronic ULT scope confirmed and acute flare excluded/handed off

Patient inputs (15)

ULT strongly indicated if ≥2 flares/yr (ACR 2020 FitzGerald strong); ACP 2017 advises shared decision in infrequent attacks

Tophus → strong ULT indication AND lower SUA target <5 mg/dL until dissolution (ACR 2020; EULAR 2016 Richette PMID 27457514)

eGFR (CKD-EPI 2021) drives allopurinol start dose (50 mg/d if eGFR<30), titration monitoring cadence, probenecid eligibility, NSAID-prophylaxis avoidance (ACR 2020; Stamp RCT PMID 28314755)

CKD ≥3 is both an ULT indication and the dominant AHS-risk and dosing modifier (ACR 2020 FitzGerald strong)

Established CVD informs febuxostat positioning (CARES PMID 29527974 vs FAST PMID 33181081 vs ALL-HEART PMID 36216006)

SE-Asian (Han Chinese/Thai/Korean) and African-American ancestry → HLA-B*5801 genotype before allopurinol (ACR 2020 FitzGerald strong — SJS/TEN risk)

Thiazide/loop diuretics raise SUA — switch to losartan (uricosuric ARB) or amlodipine where feasible (EULAR 2016 Richette PMID 27457514)

Allopurinol/febuxostat block xanthine oxidase → life-threatening 6-MP/azathioprine toxicity; absolute interaction gate before XOI

Treat-to-target analyte: <6 mg/dL general, <5 mg/dL tophaceous/severe; saturation point ~6.8 mg/dL (ACR 2020; EULAR 2016)

Pegloticase (recombinant uricase) causes haemolysis in G6PD deficiency — mandatory pre-screen before refractory step (FDA label; ACR 2020)

Uric-acid stones → ULT priority + urinary alkalinisation; uricosurics relatively contraindicated (ACR 2020 FitzGerald)

Solid-organ transplant / cyclosporine-tacrolimus → secondary hyperuricemia + colchicine/azathioprine interaction; allopurinol–azathioprine is a hard interaction (ACR 2020)

Allopurinol/febuxostat/pegloticase not established-safe in pregnancy; methotrexate is teratogenic — defer ULT or individualise (ACR 2020; special-pop branch)

Geriatric STOPP/START — colchicine + CKD + statin/CYP3A4 interaction risk; allopurinol still first-line with start-low-go-slow (Pascart Drugs Aging 2022 PMID 36437395)

Baseline LFT before allopurinol/febuxostat; AHS includes hepatitis (ACR 2020 FitzGerald)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (8)

8 need judgement
  • informationallife_threateningallopurinol_hypersensitivity_syndrome
    Fever + rash + eosinophilia + AKI/hepatitis after starting allopurinol (DRESS/SJS-TEN spectrum) (ACR 2020 FitzGerald)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningallopurinol_azathioprine_6mp_interaction
    Patient on azathioprine or 6-mercaptopurine (transplant/IBD) requiring a xanthine oxidase inhibitor — absolute interaction (ACR 2020)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningpegloticase_loss_of_response_anaphylaxis
    Pre-infusion SUA >6 mg/dL on two consecutive doses or infusion reaction — predicts anaphylaxis (FDA label; ACR 2020)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereallopurinol_ahs_interaction_risk_3way
    HLA-B*5801 positive OR high-risk ancestry, AND CKD ≥3, AND thiazide use — compounded AHS risk (ACR 2020 FitzGerald strong)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevererefractory_tophaceous_pegloticase_pathway
    Persistent tophi / SUA above target despite max XOI + uricosuric and verified adherence (ACR 2020; MIRROR Botson 2022 PMID 36099211)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereg6pd_deficiency_pegloticase_contraindication
    G6PD deficiency in a patient otherwise eligible for pegloticase (FDA label; ACR 2020)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatetophaceous_lower_target_dependency
    One or more subcutaneous tophi or radiographic erosion — SUA target drops to <5 mg/dL until dissolution (ACR 2020 FitzGerald; EULAR 2016 Richette PMID 27457514)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatefebuxostat_cv_mortality_caution
    Established cardiovascular disease and febuxostat being considered/used (CARES White NEJM 2018 PMID 29527974; FAST PMID 33181081)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

CONTEXTrequiredDrives dose adjustment
Loading…

Recommended regimen

Urate-lowering therapy — treat-to-target SUA <6 mg/dL (<5 if tophaceous/severe) (ACR 2020 FitzGerald PMID 32391934; EULAR 2016 Richette PMID 27457514)
axis: gout_ult_treat_to_targetstep 1 - Step 1 — Confirm ULT indication & substitute modifiable urate drivers (pre-pharmacologic)
Selected step "Step 1 — Confirm ULT indication & substitute modifiable urate drivers (pre-pharmacologic)" — Strong indication present (≥2 flares/yr, ≥1 tophus, radiographic erosion, CKD≥3, urolithiasis, or SUA>9 mg/dL); ACP 2017 → shared decision if infrequent attacks
  • discontinue/substitute urate-raising drug (thiazide/loop → losartan or amlodipine; review low-dose ASA)
    first line
    medication_reconciliation
    triggers: diuretic_induced_hyperuricemia, modifiable_driver_present
    Thiazide/loop diuretics raise SUA; losartan is uniquely uricosuric among ARBs — switch where cardiovascularly feasible (EULAR 2016 Richette PMID 27457514)
  • losartan
    comorbidity specific
    uricosuric_ARB
    50 mg • PO • once daily (max: 100 mg/day)
    triggers: htn_on_thiazide, needs_antihypertensive_with_urate_benefit
    Uricosuric ARB — replaces a urate-raising diuretic while modestly lowering SUA (EULAR 2016 Richette PMID 27457514)
    rxcui 52175
  • lifestyle: alcohol moderation, fructose/SSB reduction, weight loss, hydration
    add on
    lifestyle
    triggers: modifiable_lifestyle_driver
    Adjunctive — insufficient alone to reach target but reduces required ULT dose (EULAR 2016 Richette PMID 27457514; ACR 2020 conditional)

outpatient playbook — drug actions (6)

  1. 1. substitute modifiable urate driver
    switch HCTZ → losartan 50 mg PO daily where feasible • PO • daily
    trigger: Diuretic-induced hyperuricemia with antihypertensive need
    Losartan uniquely uricosuric ARB (EULAR 2016 Richette PMID 27457514)
  2. 2. allopurinol initiation
    100 mg PO daily (50 mg if eGFR<30); titrate q2–4 wk • PO • daily
    trigger: ULT indicated, HLA-B*5801 negative/low-risk, no azathioprine/6-MP
    ACR 2020 FitzGerald strong first-line; treat-to-target not CrCl-capped (Stamp PMID 28314755)
  3. 3. flare prophylaxis
    colchicine 0.6 mg PO daily/BID (or low-dose NSAID/prednisone) • PO • daily ≥3–6 mo after target
    trigger: Any ULT initiation/up-titration
    ACR 2020 strong; placebo NOT non-inferior (Stamp 2023 PMID 37652661)
  4. 4. febuxostat alternative
    40 → 80 mg PO daily • PO • daily
    trigger: Allopurinol intolerant / AHS / HLA-B*5801 positive
    ACR 2020 conditional; CV caution (CARES PMID 29527974 vs FAST PMID 33181081)
  5. 5. probenecid uricosuric
    250 mg BID → 500 mg–1 g BID • PO • BID
    trigger: Under-excretor, eGFR≥30, no stones, XOI inadequate
    ACR 2020 FitzGerald conditional add-on/alternative
  6. 6. pegloticase + methotrexate
    pegloticase 8 mg IV q2wk + MTX 15 mg PO weekly + folic acid • IV + PO • q2 weeks
    trigger: Refractory tophaceous, oral ULT failure, G6PD normal
    MIRROR — MTX raises response 38.5→71% (PMID 36099211), tophus resolution 53.8 vs 31% (PMID 37385296)

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: ≥2 gout flares in the past 12 months — strong ULT indication (ACR 2020 FitzGerald strong; EULAR 2016 Richette); One or more subcutaneous tophi — strong ULT indication, SUA target <5 mg/dL (ACR 2020 FitzGerald strong); Radiographic erosion / DECT or US double-contour urate deposition (ACR 2020; EULAR 2018 diagnostic PMID 31167758).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Chronic gout — urate-lowering therapy (treat-to-target)** (msk.gout-chronic.core.v1).
Phenotype framing: Tophaceous gout vs CPPD vs nodal/erosive osteoarthritis vs RA nodules vs xanthoma/xanthelasma; asymptomatic hyperuricemia (do NOT treat with ULT — ACR 2020 strong against); pseudo-resistance (non-adherence / under-dosing) vs true ULT resistance before escalating (ACR 2020 FitzGerald)
Scope: Adult/geriatric established or recurrent gout — the longitudinal urate-lowering arc to treat-to-target and dissolve crystal burden. Acute-flare abortive therapy is NOT in scope (route to msk.gout-acute.core.v1). Disease is curable below the MSU saturation point ~6.8 mg/dL (ACR 2020 FitzGerald PMID 32391934; EULAR 2016 Richette PMID 27457514)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Urate-lowering therapy — treat-to-target SUA <6 mg/dL (<5 if tophaceous/severe) (ACR 2020 FitzGerald PMID 32391934; EULAR 2016 Richette PMID 27457514)** — step "Step 1 — Confirm ULT indication & substitute modifiable urate drivers (pre-pharmacologic)".
1. discontinue/substitute urate-raising drug (thiazide/loop → losartan or amlodipine; review low-dose ASA) (medication_reconciliation, first line) — Thiazide/loop diuretics raise SUA; losartan is uniquely uricosuric among ARBs — switch where cardiovascularly feasible (EULAR 2016 Richette PMID 27457514)
2. losartan 50 mg PO once daily (uricosuric_ARB, comorbidity specific) — Uricosuric ARB — replaces a urate-raising diuretic while modestly lowering SUA (EULAR 2016 Richette PMID 27457514)
3. lifestyle: alcohol moderation, fructose/SSB reduction, weight loss, hydration (lifestyle, add on) — Adjunctive — insufficient alone to reach target but reduces required ULT dose (EULAR 2016 Richette PMID 27457514; ACR 2020 conditional)

Setting playbook (outpatient) — Confirm ULT indication, initiate/titrate urate-lowering therapy to target SUA <6 mg/dL (<5 if tophaceous) with anti-inflammatory prophylaxis, dissolve crystal/tophus burden, and address modifiable drivers — lifelong (ACR 2020 FitzGerald PMID 32391934; EULAR 2016 Richette PMID 27457514)
4. substitute modifiable urate driver switch HCTZ → losartan 50 mg PO daily where feasible PO daily — Diuretic-induced hyperuricemia with antihypertensive need (Losartan uniquely uricosuric ARB (EULAR 2016 Richette PMID 27457514))
5. allopurinol initiation 100 mg PO daily (50 mg if eGFR<30); titrate q2–4 wk PO daily — ULT indicated, HLA-B*5801 negative/low-risk, no azathioprine/6-MP (ACR 2020 FitzGerald strong first-line; treat-to-target not CrCl-capped (Stamp PMID 28314755))
6. flare prophylaxis colchicine 0.6 mg PO daily/BID (or low-dose NSAID/prednisone) PO daily ≥3–6 mo after target — Any ULT initiation/up-titration (ACR 2020 strong; placebo NOT non-inferior (Stamp 2023 PMID 37652661))
7. febuxostat alternative 40 → 80 mg PO daily PO daily — Allopurinol intolerant / AHS / HLA-B*5801 positive (ACR 2020 conditional; CV caution (CARES PMID 29527974 vs FAST PMID 33181081))
8. probenecid uricosuric 250 mg BID → 500 mg–1 g BID PO BID — Under-excretor, eGFR≥30, no stones, XOI inadequate (ACR 2020 FitzGerald conditional add-on/alternative)
9. pegloticase + methotrexate pegloticase 8 mg IV q2wk + MTX 15 mg PO weekly + folic acid IV + PO q2 weeks — Refractory tophaceous, oral ULT failure, G6PD normal (MIRROR — MTX raises response 38.5→71% (PMID 36099211), tophus resolution 53.8 vs 31% (PMID 37385296))

Non-pharmacologic actions:
- HLA-B*5801 genotype before allopurinol in SE-Asian/African-American ancestry (ACR 2020 FitzGerald strong)
- G6PD assay before any pegloticase pathway (FDA label; ACR 2020)
- Alcohol moderation, fructose/SSB reduction, weight loss, hydration (EULAR 2016 Richette PMID 27457514)
- Tophus surgical referral if functional impairment / nerve compression (ACR 2020 FitzGerald)
- CV risk modification — treat the gout, not the urate, outside gout (ALL-HEART PMID 36216006)

AVOID / contraindication checks:
- Allopurinol azathioprine 6mp ABSOLUTE xanthine oxidase interaction (life threatening myelosuppression — ACR 2020 FitzGerald)
- Allopurinol HLA B5801 genotype before start SE Asian African American (SJS/TEN/DRESS — ACR 2020 FitzGerald strong)
- Allopurinol STOP and NEVER rechallenge if hypersensitivity syndrome (ACR 2020 FitzGerald)
- Febuxostat CV mortality caution established CVD (CARES White NEJM 2018 PMID 29527974; FAST PMID 33181081)
- Probenecid block if eGFR<30 or uric acid stones (ACR 2020 FitzGerald)
- Pegloticase G6PD screen and STOP on loss of response (FDA label; ACR 2020)
- Pegloticase methotrexate cotherapy required for immunogenicity (MIRROR Botson 2022 PMID 36099211)
- Methotrexate absolute contraindication pregnancy and severe renal hepatic (MIRROR Botson 2022)
- Colchicine dose reduce eGFR<30 and strong CYP3A4 PGP inhibitor (ACR 2020 FitzGerald)
- Do not initiate ULT for asymptomatic hyperuricemia (ACR 2020 FitzGerald strong against)

Monitoring

Regimen monitoring:
- SUA q2-4wk during titration (ACR 2020 FitzGerald treat-to-target strong)
- SUA q6mo once at sustained target (ACR 2020 FitzGerald)
- allopurinol rash LFT first 8wk if AHS risk (ACR 2020 FitzGerald)
- LFT CBC renal first year on XOI (ACR 2020 FitzGerald)
- flare prophylaxis >=3-6mo after target reached (ACR 2020 FitzGerald strong; Stamp 2023 PMID 37652661)
- pegloticase PRE-INFUSION SUA before every dose stop if >6 x2 (FDA label; ACR 2020)
- tophus size trajectory clinical and imaging (MIRROR PMID 37385296)

Setting (outpatient) monitoring:
- SUA q2–4 wk during titration → q6 mo at sustained target (ACR 2020 FitzGerald)
- Allopurinol rash/LFT first 8 wk if AHS-risk; LFT/CBC/renal first year on XOI (ACR 2020)
- Pegloticase pre-infusion SUA before every dose — stop if loss-of-response (ACR 2020; FDA label)
- Continue prophylaxis ≥3–6 mo after target reached then taper (ACR 2020 strong; Stamp 2023 PMID 37652661)
- Tophus size clinical/imaging trajectory (MIRROR PMID 37385296)

Follow-up plan: Lifelong ULT for established gout (ACR 2020 FitzGerald strong). CV risk modification (treat the gout, not the urate, outside gout — ALL-HEART PMID 36216006). Diet/alcohol/fructose/weight counseling (EULAR 2016 Richette PMID 27457514). Cautious dose-REDUCTION deprescribing (never abrupt stop) only after years of sustained target + no tophi + no flares, with continued surveillance. Tophus surgical referral if functional impairment
- Close-out criterion: Long-term lifelong plan + counseling + deprescribing criteria documented

Monitoring phase: SUA q2–4 wk during ULT titration → q6 mo once at sustained target (ACR 2020 FitzGerald treat-to-target strong). Renal panel + LFT + CBC per agent (XOI: first-year LFT/CBC; allopurinol: rash/LFT first 8 wk in AHS-risk). Anti-inflammatory prophylaxis duration review ≥3–6 mo after target reached. Pegloticase: PRE-INFUSION SUA before every dose — rising/loss-of-response (>6 mg/dL ×2) predicts anaphylaxis → STOP. Tophus size trajectory (ACR 2020; MIRROR PMID 37385296)

Disposition

Current setting: outpatient — Confirm ULT indication, initiate/titrate urate-lowering therapy to target SUA <6 mg/dL (<5 if tophaceous) with anti-inflammatory prophylaxis, dissolve crystal/tophus burden, and address modifiable drivers — lifelong (ACR 2020 FitzGerald PMID 32391934; EULAR 2016 Richette PMID 27457514)

Disposition criteria:
- Continue outpatient ULT titration; rheumatology referral for refractory/tophaceous or pegloticase candidacy (ACR 2020 FitzGerald)
- Admit only for allopurinol hypersensitivity syndrome or pegloticase anaphylaxis (ACR 2020)

Escalation triggers (move to higher acuity):
- Allopurinol hypersensitivity syndrome (fever+rash+eosinophilia+AKI/hepatitis) → STOP, never rechallenge, ED/admit (ACR 2020 FitzGerald)
- Pegloticase infusion anaphylaxis or loss-of-response → STOP pegloticase, ED (ACR 2020; FDA label)
- True ULT resistance despite max XOI + uricosuric with tophus burden → rheumatology + pegloticase pathway (ACR 2020; MIRROR PMID 36099211)
- Suspected co-existing septic joint during an intercurrent flare → ED arthrocentesis (ACR 2020)

Patient Action Plan

**Chronic gout — urate-lowering therapy self-management plan**
Personalised values: ult_drug_and_dose, sua_target_6_or_5, flare_prophylaxis_plan, comorbid_CKD_CVD, next_sua_lab_date.

**Stable — on ULT at target urate** (green):
Triggers:
- No flares in 6+ months (ACR 2020 FitzGerald)
- SUA at target (<6, or <5 if you have/had tophi) (ACR 2020; EULAR 2016 PMID 27457514)
- Taking allopurinol/febuxostat exactly as prescribed
Actions:
- Take your urate-lowering medicine every day — never stop because you feel well (gout comes back) (ACR 2020 FitzGerald strong)
- Keep your urate blood test every 6 months (ACR 2020 FitzGerald)
- Continue flare-prevention medicine until your provider says to stop (usually ≥3–6 months after target) (ACR 2020 strong)
- Limit alcohol and sugary/fructose drinks; hydrate; aim for a healthy weight (EULAR 2016 Richette PMID 27457514)
- Tell any new prescriber you take gout medicine (some drugs interact — especially azathioprine)

**Caution — flare, rising urate, or missed doses** (yellow):
Triggers:
- A new joint flare while on ULT
- Urate level rising or above target on labs
- Missed several ULT doses / new diuretic started
Actions:
- DO NOT stop your urate-lowering medicine during a flare — keep taking it (ACR 2020 FitzGerald strong)
- Use your pre-agreed flare rescue plan (managed by the acute-gout plan) — do not start/stop ULT for the flare
- Restart any missed ULT doses and book a urate recheck
- Call your provider if flares are becoming more frequent — your dose may need titration (ACR 2020 treat-to-target)
Contact provider when:
- Two or more flares despite being on ULT
- A new tophus (lump) appears or an old one grows
- A new medicine was started that may raise urate (diuretic) or interact (azathioprine)

**Medical alert — drug reaction** (red):
Triggers:
- Rash, fever, facial swelling, or peeling skin after starting allopurinol (possible hypersensitivity) (ACR 2020 FitzGerald)
- Severe reaction during/after a pegloticase infusion (anaphylaxis)
- Dark urine + fatigue (possible haemolysis on pegloticase if G6PD-deficient)
Actions:
- STOP allopurinol and seek emergency care immediately for any rash/fever/skin reaction — do NOT take it again ever (ACR 2020 FitzGerald)
- Call emergency services for any severe infusion reaction
- Bring your full medication list including the ULT drug and dose
Contact provider when:
- Always seek emergency care for skin rash + fever on allopurinol or any severe infusion reaction (ACR 2020 FitzGerald)

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Fever + rash + eosinophilia + AKI/hepatitis after starting allopurinol (DRESS/SJS-TEN spectrum) (ACR 2020 FitzGerald)
- [LIFE_THREATENING] Patient on azathioprine or 6-mercaptopurine (transplant/IBD) requiring a xanthine oxidase inhibitor — absolute interaction (ACR 2020)
- [LIFE_THREATENING] Pre-infusion SUA >6 mg/dL on two consecutive doses or infusion reaction — predicts anaphylaxis (FDA label; ACR 2020)

Citations

- 2020 ACR Guideline for the Management of Gout (FitzGerald et al, Arthritis Care Res 2020, PMID 32391934) + 2016 EULAR management recs (Richette, PMID 27457514) + 2018 EULAR diagnostic update (PMID 31167758) + ACP 2017 (PMID 27802508). EVIDENCE GAP: no EULAR 2024 full management revision located on 2026-05-16 (see research bundle §E) [PMID:32391934](https://pubmed.ncbi.nlm.nih.gov/32391934/)
- Cited evidence (PMID 27457514) [PMID:27457514](https://pubmed.ncbi.nlm.nih.gov/27457514/)
- Cited evidence (PMID 31167758) [PMID:31167758](https://pubmed.ncbi.nlm.nih.gov/31167758/)
- Cited evidence (PMID 27802508) [PMID:27802508](https://pubmed.ncbi.nlm.nih.gov/27802508/)
- Cited evidence (PMID 29527974) [PMID:29527974](https://pubmed.ncbi.nlm.nih.gov/29527974/)

Last reconciled with current guidelines: 2026-05-22.
References
  • 2020 ACR Guideline for the Management of Gout (FitzGerald et al, Arthritis Care Res 2020, PMID 32391934) + 2016 EULAR management recs (Richette, PMID 27457514) + 2018 EULAR diagnostic update (PMID 31167758) + ACP 2017 (PMID 27802508). EVIDENCE GAP: no EULAR 2024 full management revision located on 2026-05-16 (see research bundle §E) — PMID:32391934
  • Cited evidence (PMID 27457514) — PMID:27457514
  • Cited evidence (PMID 31167758) — PMID:31167758
  • Cited evidence (PMID 27802508) — PMID:27802508
  • Cited evidence (PMID 29527974) — PMID:29527974